Copyright CNW Group 2015
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
View original source (CNW)Resverlogix Corp. on 6ix
Story so far
Earlier from Resverlogix
- Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum
- Resverlogix Announces Voting Results
- Resverlogix Provides Research and Development Update in New York City
- Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases
- Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference
Later from Resverlogix
- Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference
- Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
- Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
- Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman
- The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium
Follow Resverlogix into a list and get an email when it puts out news.
Follow Resverlogix